Teva Pharmaceutical Industries Ltd - Company Profile
Powered by 
All the sales intelligence you need on Teva Pharmaceutical Industries Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Teva Pharmaceutical Industries Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Teva Pharmaceutical Industries Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Teva Pharmaceutical Industries Ltd (Teva) is a pharmaceutical company engaged in the development, production, and marketing of generic and innovative medicines. Its main activities include manufacturing generic drugs, biosimilars, and innovative medicines, related to therapy areas of central nervous system disorders, neurodegenerative conditions, and movement disorders, dermatology, women’s health, respiratory diseases, other disease conditions, and oncology including leukemia and types of non-Hodgkin’s lymphoma. It offers medicines in various dosage forms including capsules, tablets, injectables, liquids, inhalants, creams, and ointments. It also provides over-the-counter (OTC) products and focuses on developing generic drugs. The company operates through a network of subsidiaries in North America, Europe, and international markets. Teva is headquartered in Tel Aviv, Israel.
Headquarters
Israel
Address
124 Dvora Hanevi'A St., Tel Aviv, 6944020
Website
www.tevapharm.com
Telephone
972 391 48213
No of Employees
31,173
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TEVA (TLV)
Revenue (2024)
$17.3B
4.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
186.1%
(2024 vs 2023)
Market Cap*
$41.3B
Net Profit Margin (2024)
XYZ
182.5%
(2024 vs 2023)
* As of and is in US$
Teva Pharmaceutical Industries Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Innovative Medicines: | Out-Licensing Generic Pharmaceuticals | Apriso |
| Central Nervous System | Contract Manufacturing | AndroGel |
| Respiratory | NuvaRing | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In April, the company entered into an agreement to acquire Emalex Biosciences, a biopharma company. |
| 2026 | Contracts/Agreements | In March, the company's subsidiary Teva Pharmaceuticals and Blackstone Life Sciences announced a US$400 million strategic funding agreement spread across four years to support the continued clinical development of duvakitug. |
| 2026 | Regulatory Approval | In March, the company received approval from the US FDA for Ponlimsi (denosumab-adet) as a biosimilar to Prolia. |
Competitor Comparison
| Key Parameters | Teva Pharmaceutical Industries Ltd | Merck & Co Inc | Pfizer Inc | AstraZeneca Plc | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | Israel | United States of America | United States of America | United Kingdom | United States of America |
| City | Tel Aviv | Rahway | New York City | Cambridge | Princeton |
| State/Province | Tel Aviv | New Jersey | New York | Cambridgeshire | New Jersey |
| No. of Employees | 31,173 | 75,000 | 75,000 | 96,100 | 32,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sol J. Barer, Ph.D. | Chairman | Executive Board | 2017 | 78 |
| Richard D. Francis | Chief Executive Officer; Director; President | Executive Board | 2023 | 57 |
| Eli Kalif | Chief Financial Officer; Executive Vice President | Senior Management | 2019 | 53 |
| Eric A. Hughes, MD | Chief Medical Officer; Executive Vice President - Global R&D | Senior Management | 2022 | 56 |
| Nir Baron | Chief Internal Auditor; Senior Vice President | Senior Management | 2014 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer